Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jeremy D. LeRay"'
Autor:
Mieke Ptaszynski, Elizabeth Abbott, Frank C. Richardson, Larry Dihel, Eric N. Brown, Jeremy D. Leray, John Desjardins, David L. Emerson, Raymond A. Bendele, Marta Hamilton, Blake Tomkinson
Publikováno v:
Anti-Cancer Drugs. 12:235-245
Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. Lurtotecan, a water-soluble camptothecin analog, was formulated as a liposomal drug, NX211, to enhance the delivery of drug to tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca091d9700dcb2a924e0a2f80950d332
https://doi.org/10.1097/00001813-200103000-00009
https://doi.org/10.1097/00001813-200103000-00009
Autor:
William C. Clay, Diane M. Ignar, Thomas A. Kost, John L. Andrews, J. A. Onori, Jeremy D. Leray, David L. Emerson, Sam M. Witherspoon, Katherine E. Kilpatrick
Publikováno v:
Clinical and Experimental Metastasis. 16:9-20
Tumor establishment and metastasis are dependent on extracellular matrix proteolysis, tumor cell migration, and angiogenesis. Urokinase plasminogen activator (uPA) and its receptor are essential mediators of these processes. The purpose of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b336169e941dec64957d03fc86b6b22
https://doi.org/10.1023/a:1006503816792
https://doi.org/10.1023/a:1006503816792
Autor:
April Franks, Denny J. Meyer, Karen Hart, Blake Tomkinson, Frank C. Richardson, Edward Wells, David L. Emerson, Katherine K. Richardson, Eric N. Brown, Christy Nilsson, Chris Black, Gina Sennello, Susan Karimi, Jeremy D. LeRay, Raymond A. Bendele
Publikováno v:
Cancer chemotherapy and pharmacology. 55(3)
OSI-7836 (4'-thio-beta-D-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of cancer. As with other nucleoside analogs, the proposed mechanism of action involves phosphorylation to the triphospha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e7037aeb8e0b353ea3121401793573
https://pubmed.ncbi.nlm.nih.gov/15592840
https://pubmed.ncbi.nlm.nih.gov/15592840
Autor:
Jeremy D. LeRay, Michelle Pelanne, Blake Tomkinson, Eric N. Brown, Karen Hart, David L. Emerson, Denny J. Meyer, Atherton G. Gray, Ray Bendele, Francis J. Giles
Publikováno v:
Leukemia research. 27(11)
OSI-211 (liposomal lurtotecan), was evaluated using several different dose schedules (1mg/kg, d1-5, 1.75 mg/kg d1, 3, 5 and 6 mg/kg d1, 8) in severe combined immunodeficient (SCID) mouse models of acute myelogenous leukemia (AML) and acute lymphocyti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc3a3467546d86d09a3724d591d3632
https://pubmed.ncbi.nlm.nih.gov/12859997
https://pubmed.ncbi.nlm.nih.gov/12859997
Autor:
David L. Emerson, William C. Clay, Byron Ellis, John L. Andrews, Christine R. Hoffman, Laurie K. Overton, Diane M. Ignar, Thomas A. Kost, Katherine E. Kilpatrick, Jeremy D. Leray
Publikováno v:
Gene. 190(1)
Numerous studies have demonstrated the importance of urokinase plasminogen activator (uPA) and its receptor, uPAR, in the processes of tumor progression and metastasis. Thus, the uPA/uPAR interaction may represent an important target for inhibiting m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9603750e6fd6bced965b0bc6b789bcc
https://pubmed.ncbi.nlm.nih.gov/9185859
https://pubmed.ncbi.nlm.nih.gov/9185859